Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Pharvaris N.V.
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
October 03, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Data at the Bradykinin Symposium 2024
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
August 28, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Annual Meeting of Shareholders
June 11, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
June 04, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
May 13, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 10, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
April 10, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
April 04, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
March 18, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
March 06, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
March 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
February 22, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Extraordinary Meeting of Shareholders
February 16, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present at the WSAAI Annual Meeting 2024
January 26, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
January 22, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
January 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
December 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present at the GA²LEN UCARE Conference 2023
November 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
November 15, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
November 09, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
October 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the APAAACI 2023 International Conference
October 13, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.